LAKE FOREST, Ill., Jan. 19, 2016 — (Healthcare Sales & Marketing Network) — Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8… Biopharmaceuticals, Generics, Product LaunchAkorn, Buprenorphine, Naloxone, Tobramycin (Source: HSMN NewsFeed)
Monthly Archives: January 2016
Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial
ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. (Source: Addiction)
Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial
ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. (Source: Addiction)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder. (Source: Journal of Clinical Psychopharmacology)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder. (Source: Journal of Clinical Psychopharmacology)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Our results indicate that alcohol and illicit substance use is associated with non-adherence to BUP-naloxone treatment, and suggests that CBT and efforts to promote abstinence from non-opioid substance use may improve adherence among African-Americans. These findings contribute to growing literature on understanding adherence to BUP-naloxone, which is critical to reduce morbidity and mortality. (Am J Addict 2016;XX:1-8).
PMID: 26749158 [PubMed – as supplied by publisher] (Source: American Journal on Addictions)